- Home
- ZYME vs REX Comparison
ZYME vs REX Comparison
Compare ZYME & REX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- REX
- Stock Information
- Founded
- ZYME 2003
- REX 1980
- Country
- ZYME United States
- REX United States
- Employees
- ZYME N/A
- REX N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- REX Major Chemicals
- Sector
- ZYME Health Care
- REX Industrials
- Exchange
- ZYME Nasdaq
- REX Nasdaq
- Market Cap
- ZYME 751.6M
- REX 778.2M
- IPO Year
- ZYME 2017
- REX N/A
- Fundamental
- Price
- ZYME $15.39
- REX $46.41
- Analyst Decision
- ZYME Buy
- REX Strong Buy
- Analyst Count
- ZYME 5
- REX 1
- Target Price
- ZYME $19.00
- REX $60.00
- AVG Volume (30 Days)
- ZYME 572.6K
- REX 92.2K
- Earning Date
- ZYME 10-31-2024
- REX 11-29-2024
- Dividend Yield
- ZYME N/A
- REX N/A
- EPS Growth
- ZYME N/A
- REX 166.93
- EPS
- ZYME N/A
- REX 3.92
- Revenue
- ZYME $62,199,000.00
- REX $718,079,000.00
- Revenue This Year
- ZYME $30.09
- REX N/A
- Revenue Next Year
- ZYME N/A
- REX $13.53
- P/E Ratio
- ZYME N/A
- REX $11.84
- Revenue Growth
- ZYME N/A
- REX N/A
- 52 Week Low
- ZYME $7.80
- REX $35.73
- 52 Week High
- ZYME $17.70
- REX $60.79
- Technical
- Relative Strength Index (RSI)
- ZYME 55.74
- REX 50.61
- Support Level
- ZYME $12.39
- REX $47.81
- Resistance Level
- ZYME $17.70
- REX $49.55
- Average True Range (ATR)
- ZYME 0.84
- REX 1.51
- MACD
- ZYME 0.10
- REX 0.00
- Stochastic Oscillator
- ZYME 56.50
- REX 39.15
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.